The 2026-27 Federal Budget commits $589 million to research infrastructure, trial approvals reform, and expanded Medical Research Future Fund (MRFF) investment. For clinical trial sponsors and contract research organisations (CROs) planning activity in Australia, the measures have direct operational implications. Below, we explore what has been announced, what it means in practice, and where the gaps remain.
The headline figure and what it covers
The Federal Government has described its $589 million commitment as an investment in making Australia a destination of choice for clinical trials. That framing is deliberate. Australia has consistently ranked in the top ten globally for life sciences research, with government claiming in 2025 that participation in clinical trials has already contributed more than $1.4 billion to the national economy and supported over 8,000 jobs. The budget investment is, in part, a response to competitive pressure: other jurisdictions have been faster to harmonise their approval environments (TGA registration and PBS reimbursement), and sponsors have noticed.
The $589 million is not a single program. It draws together several distinct budget lines with different timelines and mechanisms.
MRFF scaling to $1 billion annually
The most consequential long-term commitment is the Medical Research Future Fund trajectory. Disbursements are set to scale progressively from $650 million in 2025-26 to $1 billion per year by 2030-31. The MRFF funds grant programs that directly support clinical trial activity, including international trial collaborations, rare cancer and disease trials, and prevention research. Sponsors and investigator teams should expect expanded funding rounds as that ceiling rises.
The MRFF balance itself is projected to exceed $26 billion by 2028-29, meaning the fund has long-term capacity behind the commitment. This is not a one-cycle injection.
National One Stop Shop: the approvals infrastructure piece
The most operationally significant reform in the budget is the continued investment in the National One Stop Shop (NOSS) for clinical trials. The budget allocates nearly $16 million over two years to progress its development.
The NOSS is designed to replace the current patchwork of state and territory approval systems with a single national platform. Under the current environment, multi-site trials that cross jurisdictional boundaries carry significant administrative duplication. Ethics approvals, site authorisations, and reporting obligations differ between states. The NOSS will consolidate these into one end-to-end process, covering applications through to ethics approval and site authorisation.
Industry bodies have been direct about what is at stake. Without adequate NOSS funding, the Research and Development Taskforce, a collaboration between AusBiotech, Medicines Australia, and Medical Technology Association of Australia (MTAA), has warned that Australia’s clinical trial landscape risks further fragmentation. Biopharmaceutical companies may prioritise countries with more efficient systems. The $15.8 million allocation moves the NOSS forward, but the platform remains in development. Operational benefits are prospective.
PrOSPeCT and precision oncology access
The budget also proposes to provide $71.0 million over 2 years from 2026-27 to continue support for the Precision Oncology Enabling Clinical Trials (PrOSPeCT) program, which provides patients with advanced, poor-prognosis, and treatment-resistant cancers access to comprehensive genomic profiling. This matters for supply: trials operating under PrOSPeCT are typically complex, multi-arm studies with investigational product requirements that demand close coordination between clinical trial sponsors, sites, and supply chain.
What the budget does not fully resolve
The budget is not without criticism from the sector. AusBiotech welcomed the MRFF trajectory but flagged concern about the discontinuation of the Australian Economic Accelerator and further cuts to the Industry Growth Program. Both supported commercialisation of research including in the life sciences. Their removal creates a gap between early-stage research funding and the pathway to commercial translation.
There is also the question of timing. The NOSS will not transform approval timelines overnight. The platform is still in development, and sponsors planning activations in Australia over the next 12 to 18 months will be operating within the existing fragmented system. The budget signals direction; it does not yet deliver operational simplicity.
Implications for supply chain planning
For sponsors evaluating or expanding Australian trial activity, the budget changes the planning calculus in two ways.
- First, the MRFF scaling increases the volume of funded trials in Australia over the forward estimates. More grant-funded trials, particularly investigator-initiated trials and rare disease studies, means more sites require supply. The lead time between grant award and site activation is typically 12 to 24 months. Sponsors and supply partners should be positioning now.
- Second, the NOSS investment signals genuine government intent to reduce the approval friction that has historically slowed site activation in multi-jurisdictional studies. Sponsors who have previously deprioritised Australian sites due to administrative complexity should reassess. The structural conditions are improving.
Akesa supports clinical trial supply of registered comparator and standard-of-care products across Australian and APAC sites through direct sourcing from manufacturers and on-demand sourcing direct to site through its innovative Clincor platform. As trial volumes increase and approval processes consolidate, supply chain configuration, including comparator sourcing, , will need to scale accordingly.
The content published on this website is provided for general information purposes only. It does not constitute regulatory, legal, clinical, financial, or professional advice. Akesa makes no representation that content is current, complete, or applicable to any specific situation. Readers should seek appropriate professional advice before acting on any information published on this site. Content reflects Akesa’s view at the date of publication and may be updated without notice.
